title: Limits of aortic stop flow infusion chemotherapy in the treatment of advanced cancer.
abstract: BACKGROUND
  Advanced and relapsed tumors remain a challenging disease with a poor and dismal prognosis. Our choice for inoperable tumors consists in a percutaneous treatment strategy involving intra-arterial chemotherapy and hemofiltration, with previous blood stop-flow, which allows high doses of Cisplatin-cisplatinum, cis-diammine-dichloroplatinum (CDDP) and Mitomycin C (MMC) in the tumor-bearing area with minimal systemic toxicity.
  
  
  METHODS
  We analyse the morbidity and mortality associated with stop-flow in 20 patients with unresectable and/or metastatic thoraco- abdominal tumors, non responders to prior systemic chemotherapy.
  
  
  RESULTS
  In our experience, the rate of major side effects of the procedure was 31% with a mortality of 5%. The side effects were related to the radiological procedure and to the chemotherapic treatment. A 74-year-old patient died for acute kidney toxicity within 15 days after the procedure. The other transient toxicity symptoms recorded were: nausea, vomiting, increasing of creatinine levels, diplopia and appearance of necrotic ulcer associated to chemotherapic drugs. Concerning the complications related to the radiological technique, the main problem was the rupture of the balloon stop-flow catheter in four patients.
  
  
  CONCLUSIONS
  Stop-flow is a new procedure that could develop in the future, thanks to the possibility of obtaining a higher dose intensity of chemotherapic drugs in districts or organs affected by advanced tumors, with less systemic side effects. Unfortunately, the uncertain results in terms of increasing survival and the default of effective devices are to be resolved for a wider application of the procedure.
authors.affiliation: Division of Surgical Oncology, ASO S. Giovanni Battista, Molinette Hospital, University of Turin, Turin, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Zanon
authors.forename: M
authors.initials: M
authors.lastname: Goss
authors.forename: F
authors.initials: F
authors.lastname: Nicola
authors.forename: O
authors.initials: O
authors.lastname: Alabiso
authors.forename: S
authors.initials: S
authors.lastname: Zai
authors.forename: A G
authors.initials: AG
authors.lastname: Aymele
authors.forename: B
authors.initials: B
authors.lastname: Castagneto
authors.forename: M
authors.initials: M
authors.lastname: Grosso
authors.forename: A
authors.initials: A
authors.lastname: Mancini
authors.forename: C
authors.initials: C
authors.lastname: Gazzera
authors.forename: A
authors.initials: A
authors.lastname: Pacitti
authors.forename: G
authors.initials: G
authors.lastname: Martina
authors.forename: M
authors.initials: M
authors.lastname: Vaj
authors.forename: A
authors.initials: A
authors.lastname: Mattalia
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002408:Catheters, Indwelling / Q000009:adverse effects; D005260:Female; D006440:Hemofiltration / Q000009:adverse effects; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents